A single policy move out of Washington sent cannabis stocks climbing in April, but no company captured the moment quite like Akanda Corp. (AKAN), whose shares rocketed roughly 1,700% over the past month - making it one of the sharpest single-stock moves in the regulated cannabis sector this year. The catalyst was the U.S. government's move to reclassify state-regulated marijuana from Schedule I toward Schedule III, a change that carries real implications for medical research access, tax treatment, and the long-term regulatory standing of cannabis businesses across North America.
For operators tracking both public market signals and their own bottom lines, understanding what drove AKAN's move matters - not because the stock itself is a business model worth replicating, but because the policy momentum behind it is shaping investor expectations across the licensed cannabis space. Point-of-sale technology providers, compliance software vendors, and dispensary operators watching capital flows into the sector would do well to pay attention; if you want context on where retail infrastructure investment tends to follow, check it out. Rescheduling, even partial, tends to unlock spending at the store level - on compliance systems, inventory management tools, and the kind of seed-to-sale tracking infrastructure that regulators increasingly require.
Why a 534,000-Share Float Does What 380 Million Shares Cannot
Here's the mechanical reality behind AKAN's move. The company's total float currently sits at approximately 534,420 shares - a figure that arrived after a sequence of reverse stock splits, including a 1-for-3.125 split last year, a 1-for-5 split in January, and a further adjustment last month. Compare that to peers: Canopy Growth Corp. carries roughly 380.82 million shares in its float, Cronos Group sits near 379.05 million, and Tilray Brands operates with more than 119 million. When retail traders rotate into a cannabis stock with a float measured in the hundreds of thousands rather than the hundreds of millions, even modest buying pressure produces outsized price movement. That's not a business thesis - it's arithmetic, and traders on Stocktwits said exactly that, with message volume surging more than 231,000% over the past month.
Short interest has climbed alongside the rally, now sitting at 4.7% - its highest level in four months. That dynamic creates a familiar pressure loop: a thin float, rising short positions, and retail momentum feeding on itself. The broader cannabis peer group logged meaningful gains too - Trulieve Cannabis up roughly 94%, Canopy Growth up around 30%, IGC Pharma up about 25%, and Aurora Cannabis up approximately 12% - but none came close to matching AKAN's percentage move, which speaks less to fundamental business performance and more to how float mechanics amplify policy-driven sentiment in micro-cap names.
What Akanda Actually Operates - and What It Does Not Yet
Strip away the trading activity and Akanda is a company in transition. Its primary cannabis asset is a cultivation site on Gabriola Island in British Columbia, currently operating under a hemp cultivation license while the company pursues a full THC cultivation license from Health Canada. Commercial THC production has not started. The company has been evaluating the security infrastructure required for licensing compliance - perimeter controls, surveillance systems, access management, and secure storage - all standard requirements under Health Canada's cannabis licensing framework for facilities handling THC and CBD activities.
That's a meaningful distinction for anyone assessing Akanda against vertically integrated multi-state operators or licensed producers with established wholesale supply chains. The company does not currently generate revenue from THC flower or derivatives. Its earlier international exposure - a cultivation unit in Lesotho that ceased operations following an unauthorized liquidation ordered by the High Court of Lesotho in 2022, and a UK distribution unit called Canmart that was discontinued last year due to licensing renewal costs and litigation exposure - have both been wound down. What remains is a Canadian licensing buildout, a stated focus on Canada and Europe, and something operationally unusual for a cannabis company: a telecom infrastructure business.
The Telecom Hedge - and What It Signals About Cannabis Business Risk
Through its unit First Towers & Fiber, Akanda has been expanding a dark-fiber network across Central Mexico, recently adding roughly 200 kilometers of infrastructure tied to approximately $2 million in contracted cash flow over 10 years. The move is deliberate diversification - contract-based recurring revenue alongside an early-stage cannabis licensing buildout is a structure designed to reduce the volatility exposure that comes with operating exclusively in regulated cannabis markets.
That tension is real and well understood by cannabis operators. Pure-play cannabis companies face 280E tax treatment in the U.S. that disallows standard business deductions, ongoing excise tax obligations, licensing renewal costs, compliance expenditures, and the cost of maintaining compliant packaging, lab testing protocols, and COA documentation - none of which pause during a policy transition. Adding non-cannabis contracted revenue is one way to cushion that exposure. Whether Akanda's telecom position ultimately stabilizes the business or simply dilutes its cannabis focus is a fair question, but the structure reflects a broader reality: licensed cannabis operators increasingly look for revenue sources that don't carry the same regulatory drag.
What the Rally Actually Signals for the Sector
The rescheduling movement has done something concrete: it has reintroduced institutional and retail attention to cannabis equities that had largely moved on. For dispensary owners and multistate operators, the downstream implications of a Schedule III reclassification include potential relief from 280E's full weight, expanded pathways for medical cannabis research, and a clearer regulatory signal to banking partners and payment processors who have long treated cannabis businesses as high-risk by default. None of that happens overnight. But the direction matters.
AKAN's 1,700% move is, to be direct about it, a trading event - not a fundamental revaluation of the company's licensed cannabis business. The float mechanics explain the magnitude; the policy shift explains the timing. What it does reflect, more broadly, is how quickly capital and attention move through the cannabis sector when Washington signals regulatory change. Operators, technology vendors, and compliance professionals watching from the B2B side of the industry would do well to treat this moment less as a stock story and more as a leading indicator of where regulatory momentum is heading.